1. "Neuroblastoma Service"
Formats
  1. Journal Article (509)
  2. Meeting Abstract (295)
  3. Review (17)
  4. Book Section (14)
  5. Conference Paper (14)
  6. Editorial (5)
  7. Correspondence (2)
  8. Book Whole (1)
  9. Guidelines (1)
Groups
  1. Neuroblastoma Service (858)
  2. Pediatrics, Department of (858)
  3. GSK Faculty (682)
  4. Tow Center for Developmental Oncology (TCDO) (677)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (650)
  6. Center for Molecular Imaging and Biotechnology (427)

More Groups

People
  1. Nai-Kong Cheung (648)
  2. Brian Kushner (311)
  3. Shakeel Modak (249)
  4. Kim Kramer (176)
  5. Steven Larson (109)
  6. Stephen Roberts (107)

More People

Years
  1. 2025 (10)
  2. 2024 (26)
  3. 2023 (36)
  4. 2022 (44)
  5. 2021 (41)
  6. 2020 (49)

More Years

Publications
  1. Pediatric Blood and Cancer (115)
  2. Journal of Clinical Oncology (98)
  3. Cancer Research (41)
  4. Journal of Nuclear Medicine (36)
  5. Neuro-Oncology (32)
  6. Clinical Cancer Research (27)

More Publications

Publishers
  1. Wiley Periodicals, Inc (119)
  2. American Association for Cancer Research (102)
  3. American Society of Clinical Oncology (101)
  4. Elsevier Inc. (55)
  5. Oxford University Press (42)
  6. Society of Nuclear Medicine (36)

More Publishers

Results (858)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neuroblastoma: Pathology and genetics
    Book Section

    Cheung, N. K. V.; Lopez-Rodrigo, E.; Boffetta, P.; Hainaut, P. Encyclopedia of Cancer. 3rd ed (2019)

    Fulltext@MSK | Save
  • Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
    Journal Article

    Durham, B. H.; Lopez Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S. X.; Pastore, A.; Yoshimi, A.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Biodistribution and dosimetry of intraventricularly administered (124)I-omburtamab in patients with metastatic leptomeningeal tumors
    Journal Article

    Pandit-Taskar, N.; Zanzonico, P. B.; Kramer, K.; Grkovski, M.; Fung, E. K.; Shi, W.; Zhang, Z.; Lyashchenko, S. K.; Fung, A. M.; Pentlow, K. S.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Silencing Fc domains in T cell-engaging bispecific antibodies improves t-cell trafficking and antitumor potency
    Journal Article

    Wang, L.; Hoseini, S. S.; Xu, H.; Ponomarev, V.; Cheung, N. K.
    Cancer Immunology Research (2019)

    Fulltext@MSK | Save
  • ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures
    Journal Article

    Qadeer, Z. A.; Valle-Garcia, D.; Hasson, D.; Sun, Z.; Cook, A.; Nguyen, C.; Soriano, A.; Ma, A.; Griffiths, L. M.; Zeineldin, M.; more...
    Cancer Cell (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of intraventricular 131I-labeled monoclonal antibody 8H9 targeting the surface glycoprotein B7-H3
    Meeting Abstract

    Kramer, K.; Pandit-Taskar, N.; Donzelli, M.; Suzanne, W.; Zanzonico, P.; Humm, J.; Haque, S.; Souweidane, M.; Greenfield, J.; Carrasquillo, J.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Preliminary tolerability assessment of naxitamab (humanized anti-GD-2 monoclonal antibody) therapy in a phase 2 osteosarcoma trial
    Meeting Abstract

    Dela Cruz, F.; Chou, A.; Roberts, S.; Mauguen, A.; Bonura, J.; Hilliard, J.; Namuduri, M.; Ortiz, M.; Slotkin, E.; Wexler, L.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for high-risk neuroblastoma: Efficacy against histologically-evident primary refractory metastases in bone marrow
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treament low immunogenicity, and major responses in a phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save